AGC Biologics has partnered with Takara Bio to collaborate on a prophylaxis DNA vaccine, with AGC Biologics manufacturing the plasmid DNA intermediate for the vaccine. The vaccine will be developed based on Osaka University and AnGes, Inc.’s expertise of developing plasmid DNA products. “We are working hard in this fight against COVID-19,” said Takara Bio’s CEO Koichi Nakao. “We are grateful for the support of AGC Biologics. This partnership will help us move saf...